A Phase 1 Single Center Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy

Beteiligte Wissenschaftlerin:
Dr. rer. medic. M. Eveslage

Studienleitung:
Univ.-Prof. Dr. med. Walter Stummer